


FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

• By Susan Bernstein
• By Michael Putman, MD
• By Reuters Staff
• By Thomas R. Collins
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.